GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351 on ClinicalTrials.gov · last registry update 2024-04-16

Stopped early, having planned 15 participants. The sponsor logged completion for July 2019. Primary outcome, as filed: Change From Baseline in Urinary Albuminuria Levels. exenatide is approved in the US, but not for chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University at Buffalo
Sponsor type: Other
Enrollment: 15
Started: 2017-01-10
Primary completion: 2019-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Urinary Albuminuria Levels

Conditions studied

Type2 Diabetes · Kidney Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.